Q: Why will ACE be confined to China and not conducted in centers all over the world?
Q: ACE研究为何选择在中国开展?
A: The Western Pacific region has the largest number of patients with diabetes, approximately 39.8 million of whom live in China. By comparison, the Western Pacific region also has the highest number of people with prediabetes, the target group for ACE.
Glucobay, the study drug, was approved for the treatment of prediabetes in China in 2002 and since then is well accepted and widely used across the whole country for this condition, besides its broad use in the treatment of type 2 diabetes since 1995. Chinese physicians are very experienced and knowledgeable about the use of Glucobay??, maximizing the chance of patient compliance over the study period. The results will have relevance to the global community since the relationship of hyperglycaemia and CVD is similar to Asian and Caucasian patients.
In addition ACE is being coordinated by an independent study center in Europe and steered by an interdisciplinary, globally relevant group of leading experts.
A: 在世界范围内,西太平洋地区的糖尿病患者数量最多,其中中国大约有3980万。相对而言,西太平洋地区的糖尿病前期患者数量也是最多的,而这些人群正是ACE研究的目标人群,因此ACE研究选择在中国开展。
而且,从1995年开始,ACE研究所用药物——拜唐苹就广泛地用于2型糖尿病治疗,之后中国在2002年获批使用拜唐苹进行糖尿病前期的治疗,从此这一药物在全国范围内得到了医患的接受并广泛使用,中国内科医生也由此对拜唐苹的临床应用积累了丰富的经验,这对于研究期间获得良好的依从性是十分重要的。鉴于高血糖和CVD之间的关系在亚洲人群和高加索人群中的一致性,在中国开展的ACE研究结果可推及全球。此外,ACE研究由欧洲独立的研究中心进行协调,由跨学科的全球相关领域权威专家组成指导委员会。